U.S. FDA panel: data support safety, efficacy of Merck allergy drug
Jan 28 (Reuters) - Merck & Co's experimental allergy drug, Ragwitek, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday.
The panel voted 6 to 2, with one abstention, that data supported the drug's efficacy. It voted 8 to 0, with one abstention, that it supported the drug's safety.
Ragwitek is designed to treat allergic reaction to short ragweed pollen.
- Crimea votes to join Russia, Obama orders sanctions |
- Man called Bitcoin's father denies ties, leads LA car chase
- Apple loses bid for U.S. ban on Samsung smartphone sales
- Nine-month-old baby may have been cured of HIV, U.S. scientists say
- Exclusive: Russia wants IMF to move ahead on reforms without U.S. - sources